These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 30723876)

  • 21. Plazomicin: A New Aminoglycoside.
    Saravolatz LD; Stein GE
    Clin Infect Dis; 2020 Feb; 70(4):704-709. PubMed ID: 31328228
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Abdelraouf K; Kim A; Krause KM; Nicolau DP
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866866
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the Bactericidal Activity of Plazomicin and Comparators against Multidrug-Resistant Enterobacteriaceae.
    Thwaites M; Hall D; Shinabarger D; Serio AW; Krause KM; Marra A; Pillar C
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866876
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011-2012.
    Walkty A; Adam H; Baxter M; Denisuik A; Lagacé-Wiens P; Karlowsky JA; Hoban DJ; Zhanel GG
    Antimicrob Agents Chemother; 2014 May; 58(5):2554-63. PubMed ID: 24550325
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activity of Plazomicin against Enterobacteriaceae isolates carrying genes encoding aminoglycoside-modifying enzymes most common in US Census divisions.
    Castanheira M; Davis AP; Serio AW; Krause KM; Mendes RE
    Diagn Microbiol Infect Dis; 2019 May; 94(1):73-77. PubMed ID: 30661726
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of plazomicin compared to other clinically relevant aminoglycosides in carbapenem-resistant Enterobacteriaceae.
    Clark JA; Kulengowski B; Burgess DS
    Diagn Microbiol Infect Dis; 2020 Oct; 98(2):115117. PubMed ID: 32755805
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Can Plazomicin Alone or in Combination Be a Therapeutic Option against Carbapenem-Resistant Acinetobacter baumannii?
    García-Salguero C; Rodríguez-Avial I; Picazo JJ; Culebras E
    Antimicrob Agents Chemother; 2015 Oct; 59(10):5959-66. PubMed ID: 26169398
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New Drugs for Multidrug-Resistant Gram-Negative Organisms: Time for Stewardship.
    Jean SS; Gould IM; Lee WS; Hsueh PR;
    Drugs; 2019 May; 79(7):705-714. PubMed ID: 30972660
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Walkty A; Karlowsky JA; Baxter MR; Adam HJ; Zhanel GG
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373806
    [TBL] [Abstract][Full Text] [Related]  

  • 30. All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies.
    Lodise TP; Bassetti M; Ferrer R; Naas T; Niki Y; Paterson DL; Zeitlinger M; Echols R
    Expert Rev Anti Infect Ther; 2022 May; 20(5):707-719. PubMed ID: 34937518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Choice of therapeutic interventions and outcomes for the treatment of infections caused by multidrug-resistant gram-negative pathogens: a systematic review.
    Nørgaard SM; Jensen CS; Aalestrup J; Vandenbroucke-Grauls CMJE; de Boer MGJ; Pedersen AB
    Antimicrob Resist Infect Control; 2019; 8():170. PubMed ID: 31709047
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aminoglycoside Resistance: Updates with a Focus on Acquired 16S Ribosomal RNA Methyltransferases.
    Wachino JI; Doi Y; Arakawa Y
    Infect Dis Clin North Am; 2020 Dec; 34(4):887-902. PubMed ID: 33011054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Simulated Application of the Hartford Hospital Aminoglycoside Dosing Nomogram for Plazomicin Dosing Interval Selection in Patients With Serious Infections Caused by Carbapenem-Resistant Enterobacterales.
    Asempa TE; Kuti JL; Seroogy JD; Komirenko AS; Nicolau DP
    Clin Ther; 2019 Aug; 41(8):1453-1462. PubMed ID: 31248681
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
    Sharma R; Park TE; Moy S
    Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An update on the management of urinary tract infections in the era of antimicrobial resistance.
    Bader MS; Loeb M; Brooks AA
    Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In-vitro activity of several antimicrobial agents against methicillin-resistant Staphylococcus aureus (MRSA) isolates expressing aminoglycoside-modifying enzymes: potency of plazomicin alone and in combination with other agents.
    López Díaz MC; Ríos E; Rodríguez-Avial I; Simaluiza RJ; Picazo JJ; Culebras E
    Int J Antimicrob Agents; 2017 Aug; 50(2):191-196. PubMed ID: 28577932
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes.
    Nutman A; Lellouche J; Temkin E; Daikos G; Skiada A; Durante-Mangoni E; Dishon-Benattar Y; Bitterman R; Yahav D; Daitch V; Bernardo M; Iossa D; Zusman O; Friberg LE; Mouton JW; Theuretzbacher U; Leibovici L; Paul M; Carmeli Y;
    Clin Microbiol Infect; 2020 Sep; 26(9):1185-1191. PubMed ID: 32251844
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and
    Cruz-López F; Martínez-Meléndez A; Morfin-Otero R; Rodriguez-Noriega E; Maldonado-Garza HJ; Garza-González E
    Front Cell Infect Microbiol; 2022; 12():884365. PubMed ID: 35669117
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches.
    Karaiskos I; Giamarellou H
    Expert Opin Pharmacother; 2014 Jul; 15(10):1351-70. PubMed ID: 24766095
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ESCMID-EUCIC clinical guidelines on decolonization of multidrug-resistant Gram-negative bacteria carriers.
    Tacconelli E; Mazzaferri F; de Smet AM; Bragantini D; Eggimann P; Huttner BD; Kuijper EJ; Lucet JC; Mutters NT; Sanguinetti M; Schwaber MJ; Souli M; Torre-Cisneros J; Price JR; Rodríguez-Baño J
    Clin Microbiol Infect; 2019 Jul; 25(7):807-817. PubMed ID: 30708122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.